Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 27,752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 2 Interventional Results available

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

NCT03406377
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
OPK-88003, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Huntington Park, California • Los Angeles, California • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 14, 2026, 2:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

NCT04570501
View directory record Official record
Conditions
Covid19
Interventions
Angiotensin-(1-7), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Inflammation and Daily Life Study

NCT03771612
View directory record Official record
Conditions
Inflammation
Interventions
Naproxen, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 60 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

NCT06785012
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-89495120, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

NCT00153101
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
31,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
100
States / cities
Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 14, 2026, 2:23 PM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

NCT01049919
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
Bone marrow concentration device, Placebo procedure (sham)
Device · Procedure
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
25
States / cities
Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741
View directory record Official record
Conditions
DENV-3 Controlled Human Infection Model
Interventions
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

NCT00069641
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
iduronate-2-sulfatase enzyme replacement therapy, Placebo
Biological
Lead sponsor
Shire
Industry
Eligibility
5 Years to 25 Years · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
4
States / cities
Oakland, California • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 14, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

NCT00727194
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 14, 2026, 2:23 PM EDT
Not listed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

NCT03252353
View directory record Official record
Conditions
Acromegaly
Interventions
octreotide capsules, Matching placebo
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 14, 2026, 2:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Psoriatic Arthritis Study of Izokibep

NCT05623345
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

NCT00628095
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CE-224,535, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Mesa, Arizona • DeBary, Florida • Lake Mary, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 14, 2026, 2:23 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

NCT04386577
View directory record Official record
Conditions
Aging
Interventions
Vitamin D3 (cholecalciferol), fish oil
Dietary Supplement · Drug
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 14, 2026, 2:23 PM EDT
Recruiting Phase 3 Interventional

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

NCT05834777
View directory record Official record
Conditions
Intradialytic Hypotension
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Testosterone Administration and ACL Reconstruction in Men

NCT01595581
View directory record Official record
Conditions
Muscle Atrophy, ACL Reconstruction, Trauma, Osteoarthritis
Interventions
Testosterone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

NCT00154219
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Lumiracoxib (drug)
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

NCT00622700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Robots Paired With tDCS in Stroke Recovery

NCT01726673
View directory record Official record
Conditions
Stroke
Interventions
Transcranial Direct Current Stimulation (tDCS), Placebo sham
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

NCT04535141
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Olanzapine 5 MG, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

NCT02330094
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Pectoralis and Serratus Muscle Blocks

NCT03743194
View directory record Official record
Conditions
Post Operative Pain Control
Interventions
Exparel 266 MG Per 20 ML Injection, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 14, 2026, 2:23 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

NCT01802866
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ACU-4429, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
55 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 2:23 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions
NS-229, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Denver, Colorado • Rochester, Minnesota • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 14, 2026, 2:23 PM EDT